To assess in vivo efficacy and toxicity, we administered a mouse TLK2 ASO alone or in combination with gilteritinib in a murine model of AML.<h4>Results</h4>TLK2 ASO treatment resulted in a dose-dependent reduction of TLK2 mRNA levels and decreased cell viability in FLT3-mutant AML cell lines, with enhanced cytotoxicity observed when combined with gilteritinib. The gene discussed is FLT3; the disease is acute myeloid leukemia.